Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Mercury Biopharmaceutical's Debt-to-EBITDA or its related term are showing as below:
ROCO:6932'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.55 Med: -1.09 Max: -0.47
Current: -1.09
During the past 7 years, the highest Debt-to-EBITDA Ratio of Mercury Biopharmaceutical was -0.47. The lowest was -1.55. And the median was -1.09.
ROCO:6932's Debt-to-EBITDA is ranked worse than 100% of 682
companies
in the Drug Manufacturers industry
Industry Median: 1.635
vs ROCO:6932: -1.09
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Mercury Biopharmaceutical Debt-to-EBITDA Related Terms
Mercury Biopharmaceutical Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Biopharmaceutical Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mercury Biopharmaceutical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Mercury Biopharmaceutical (ROCO:6932) has a Debt-to-EBITDA of -1.27 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mercury Biopharmaceutical. According to the industry distribution chart, Mercury Biopharmaceutical ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Mercury Biopharmaceutical's Debt-to-EBITDA too high?
Mercury Biopharmaceutical's current Debt-to-EBITDA is -1.27. Based on the distribution chart, Mercury Biopharmaceutical ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mercury Biopharmaceutical has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mercury Biopharmaceutical ranks #999999 out of 682 companies for Debt-to-EBITDA. This places Mercury Biopharmaceutical in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mercury Biopharmaceutical. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mercury Biopharmaceutical's current Debt-to-EBITDA is -1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.25 — trading 85.4% below its estimated fair value. The current Debt-to-EBITDA is -1.27. Mercury Biopharmaceutical's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Debt-to-EBITDA is -1.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?
Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued.
The current stock price of NT$5.25 is trading 85.4% below its estimated GF Value™ of NT$36.00.
GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:6932:
Debt-to-EBITDA: -1.27
GF Value™: NT$36.00 vs. price of NT$5.25 (85.4% below fair value)
No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
31GF Score
Get the complete analysis for ROCO:6932
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6932 has been successfully added to your 
